Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 1
1964 3
1973 1
1974 1
1975 2
1976 1
1979 1
1980 4
1981 4
1982 2
1983 1
1984 4
1985 6
1986 7
1987 9
1988 9
1989 8
1990 7
1991 13
1992 13
1993 24
1994 30
1995 46
1996 53
1997 44
1998 68
1999 89
2000 79
2001 89
2002 104
2003 115
2004 143
2005 145
2006 219
2007 179
2008 229
2009 254
2010 305
2011 367
2012 425
2013 505
2014 560
2015 623
2016 635
2017 664
2018 738
2019 774
2020 954
2021 1169
2022 1348
2023 1231
2024 1475
2025 1643
2026 95

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,917 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.
van Vollenhoven RF, Wang L, Merrill JT, Liu Y, Bao C, Li F, Hu J, Huang C, Zhao J, Huang C, Mo H, Wei W, Lu F, Li J, Zhao D, Wang W, Li L, Zuraw Q, Wang X, Wang X, Fang J, Zhang F; 18C010 Trial Investigators. van Vollenhoven RF, et al. Among authors: fang j. N Engl J Med. 2025 Oct 16;393(15):1475-1485. doi: 10.1056/NEJMoa2414719. N Engl J Med. 2025. PMID: 41092329 Clinical Trial.
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC.
Fang W, Wu L, Meng X, Yao Y, Zuo W, Yao W, Xie Y, Zhang Y, Cui J, Zhang Y, Li X, Zhuang W, Fang J, Wang Q, Jiang W, Li K, Bai Y, Luo Y, Ma F, Yu Y, Zheng W, Liu Z, Yang B, Ma R, Fang Y, Yang R, Jiang L, Hu J, Yang J, Diao Y, Jin X, Ge J, Yang Y, Zhang L. Fang W, et al. Among authors: fang j. N Engl J Med. 2026 Jan 1;394(1):13-26. doi: 10.1056/NEJMoa2512071. Epub 2025 Oct 19. N Engl J Med. 2026. PMID: 41124220 Clinical Trial.
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.
Chen Z, Yang F, Jiang Z, Sun L, Wu L, Han Z, Fan Y, Zhao Y, Li X, Xu H, Meng X, Liu Y, Zhang Z, Luo H, Ma X, Ma X, Shi Q, Zhang Z, Yang R, Wang P, Pan P, Ai X, Li J, Pu X, Wang Z, Fang J, He M, He Y, Guo S, Li J, Wang H, Zhang J, Chu Q, Liu X, Ying S, Wu H, Sun H, Ji Y, Zhou M, Cao C, Tang K, Li Z, Li D, Zhang Z, Li J, Zhou J, Yang H, Du Y, Yang H, Shi J, Chen H, Li W, Lu D, Hu M, Maxwell Wang Z, Li B, Xia M, Lu S. Chen Z, et al. Among authors: fang j. Lancet. 2025 Nov 1;406(10515):2078-2088. doi: 10.1016/S0140-6736(25)01848-3. Epub 2025 Oct 19. Lancet. 2025. PMID: 41125109 Clinical Trial.
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.
Sheng X, Zeng G, Zhang C, Zhang Q, Bian J, Niu H, Li J, Shi Y, Yao K, Hu B, Liu Z, Liao H, Yu Z, Jin B, Zhao P, Yang T, Liu X, Qin Y, Xue X, Gou X, Huang J, Gu J, Qi X, Zhang L, Ma G, Liu B, Fang J, Jiang S, He Z, Zhou A, Guo J; RC48-C016 Trial Investigators. Sheng X, et al. Among authors: fang j. N Engl J Med. 2025 Dec 11;393(23):2324-2337. doi: 10.1056/NEJMoa2511648. Epub 2025 Oct 19. N Engl J Med. 2025. PMID: 41124210 Clinical Trial.
Streptococcus anginosus-derived methionine promotes gastric cancer progression.
Zhou CB, Zhao LC, Qin Y, Yu J, Li W, Feng Q, Tong X, Abuduaini R, Lu SY, Tang H, Zhang YX, Cui Y, Xiao L, Song LH, Ni LK, Wu K, Zhong H, Jiang YC, Zou Y, Leng XX, Wang M, Zhao WY, Wang CJ, Liu Q, Zhang JQ, Hu C, Chen YX, Yao YF, Zhu S, Fang JY. Zhou CB, et al. Among authors: fang jy. Gut. 2026 Jan 2:gutjnl-2025-336966. doi: 10.1136/gutjnl-2025-336966. Online ahead of print. Gut. 2026. PMID: 41482458
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
Yang JC, Wang M, Doucet L, Fan Y, Lv D, Sun M, Huang D, Greillier L, Planchard D, Hong Q, Mazieres J, Felip E, Li X, Hu Y, Fang J, Bazhenova L, Ghiringhelli F, Cobo Dols MA, Rodriguez LP, Bearz A, Pellini B, Kim YJ, Bosch-Barrera J, Shim BY, Luo YH, Tiseo M, Yang TY, Carcereny E, Memmott RM, Zalcman G, de Castro Carpeno J, Di Noia V, Parra HS, Streich G, Lee DH, Shum E, Han JY, Jaime JC, Brungs D, John T, D'Arcangelo M, Joaquin AB, Liu G, Antonuzzo L, Hinojal GF, Le X, Zheng L, Jänne PA; WU-KONG1B. Yang JC, et al. Among authors: fang j. J Clin Oncol. 2025 Oct 10;43(29):3198-3208. doi: 10.1200/JCO-25-00788. Epub 2025 Sep 9. J Clin Oncol. 2025. PMID: 40923280 Clinical Trial.
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity.
Singh S, Fang J, Jin H, Van De Velde LA, Cortes A, Chen J, Natarajan S, Poon E, Wu Q, Morton CL, Woolard MA, Quarni W, Steele JA, Connelly JP, He L, Thorne R, Turner G, Confer T, Johnson M, Caufield WV, Freeman BB 3rd, Lockey T, Murphy AJ, Murray PJ, Owa T, Pruett-Miller SM, Wang R, Chesler L, Park JR, Davidoff AM, Easton J, Chen X, Thomas PG, Yang J. Singh S, et al. Among authors: fang j. Nat Commun. 2025 Sep 17;16(1):8287. doi: 10.1038/s41467-025-63979-x. Nat Commun. 2025. PMID: 40962798 Free PMC article.
13,917 results
You have reached the last available page of results. Please see the User Guide for more information.